Mechanisms of PARPi Resistance in BRCA1/2-associated High Grade Serous Ovarian Carcinoma

Project summary

PARP inhibitor (PARPi) therapy has improved survival in high-grade serous ovarian cancer (HGSOC), especially in patients with BRCA1 and BRCA2 mutations. However, almost 50% of patients have disease recurrence, suggesting resistance to PARPi therapy. We seek to study tumors from patients with HGSOC receiving PARPi therapy and will use novel techniques to analyze the DNA, RNA and tumor microenviroment. The goal of the study is to understand how PARPi resistance occurs so that we can overcome it with new treatments and improve survival in patients with HGSOC and BRCA1/2 mutations.

This grant was made possible in part by a generous donation from Jennifer Willett in memory of Lynne Willett.